EMA Recommends Extension of Therapeutic Indications for Zanubrutinib
New indication concerns the treatment of adult patients with CLL
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast Cancers to PARP Inhibition
Activity of talazoparib in the context of homologous recombination pathway gene mutations beyond gBRCA1/2
Combination of Temozolomide and Capecitabine Associated with Improved PFS Compared to Temozolomide Alone in Advanced Pancreatic NETs
ECOG-ACRIN E2211 shows also that MGMT deficiency is associated with tumour response
EMA Recommends Extension of Indications for Cemiplimab
New indication concerns the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy
Low-Pass Genomic Instability Characterisation Assay Identifies Germline Mismatch Repair Deficiency and Risk of Cancer Onset
LOGIC tool for the diagnosis of MMRD in multiple cancer types and in normal tissues
EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Vipivotide Tetraxetan
It is indicated for the treatment of adult patients with progressive PSMA-positive mCRPC
Long-Term Clinical Benefit with Nivolumab Plus Ipilimumab Extends Beyond Treatment Discontinuation in Patients with Metastatic NSCLC, Regardless of PD-L1 Expression
CheckMate 227 Part 1 efficacy and safety data with a minimum follow-up of 5 years
Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in Patients with Previously Treated Metastatic Uveal Melanoma
Findings from the phase II expansion of the IMCgp100-102 study
Long-Term Follow-Up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options for Recurrent or Metastatic HNSCC
Findings from a post hoc analysis of KEYNOTE-048 after an approximately 4-year follow-up
FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated with Cisplatin in Paediatric Patients with Localised, Non-metastatic Solid Tumours
Efficacy was evaluated in SIOPEL 6 and COG ACCL0431 studies
Second Interim Analysis Shows OS Improvement with Adjuvant Olaparib for Germline BRCA1/2-associated, HER2-negative Early Breast Cancer
Findings from a pre-specified second interim analysis of overall survival and updates in other OlympiA study endpoints
PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments According to ESCAT Levels I or II, But Not Beyond These Levels
Findings from a pooled data analysis of the SAFIR02-BREAST and SAFIR-PI3K studies